4Szefler S J. Advancesin pediatricasthmain2007 [J ]. JAllergy- Clinlm-munol, 2008, 121(3): 614.
5Wong W S, Zhu H, Liao W P. Cysteinyl leukotriene receptor antagonistMK- 571 alters bmuchoalveolar lavage fluid proteome in a mouse asth. innmodel[J]. Eur JPhamuwol, 2007, 575(1-3): 134.
6Knorr B, Fmnehi I M, Bissard H, et al. Montelukast, a leukotriene re - ceptor antagonist, for the treatment of persistent asthnla in children 2 In 5 years[J]. Pediatrics, 2005, 108 (5): E48.
7Stelmach I, Grzelewski T. Bobmwska - Korzeniowska M, et al. A randomized, double - blind trialof the effect of anti - asthma treatment onlung function in children with asthma[J]. Pulm Pharrnacol Ther, 2007, 20(6) : 691.
8Stelmach I, Grzelewski T, Bobmwska - Korzeniowska M, et al. A ran - domized, double - blind trialof the effect of anti - asthma treatment onlung function in children with asthma[J ]. Pulm Pharmacol Ther, 2007, 20(6) : 691.
3Mita H,Turikisawa N, Yamada T,et al. Quantification of leukotriene B4 glucuronide in human urine [ J ]. Prostaglandins Other Lipid Medlar, 2007,83( 1 ) :42 -49.
4Montuschi P, Mondino C, Koch P,et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma [ J J. J Allergy Clin Immunol, 2006,118 ( 2 ) : 347 - 353.
5Kato A, Schleimer RP. Beyond inflammation:Airway epithelial cells are at the interface of innate and adaptive immunity [ J ]. Curr Opin Immunol,2007,19(6) :711 -720.
6Davidson AB, Lee TH, Scanlon PD, et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjeets[ J ]. Am Rev Respir Dis, 1987,135(2) :333 -337.
7Negri J,Early SB,Steinke JW,et al. Corticosteroids as inhibitors of cysteinyl leukotriene metabolic and signaling pathways [ J ]. J Allergy Clin Immunol,2008,121 (5) : 1232 - 1237.
8Mauad T,Bel EH, SterkP J. Asthma therapy and airway remodeling[ J ]. J Allergy Clin Immunol,2007,120(5 ) :997 - 1009.
9Gyllfors P, Dahle SE, Kumlin M, et al. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate [ J ]. J Allergy Clin Immunol,2006 ,118 ( 1 ) :78 - 83.
10Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders : Is there a ease for revisiting leukotrienes as therapeutic targets [ J ]?Inflammopharmacology, 2006, 14 (1):10-16.
6Bai T R. Evidence for airway remodeling in chronic asthma [ J ]. Curr Opin Allergy Clin lmmuno1,2010,10( 1 ) :82-86.
7Lee Y M, Park J S, Hwang J H, et al. High resolution CT findings in patients with near-fatal asthma. Comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment [ J ]. Chest, 2004,.
8Contoli M, Baraldo S, Marku B, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease:5-year followup[ J]. J Allergy Clin lmmunol,2010,125 (4) : 830-837.
9Brinke A T. Risk factors associated with irreversible air flow obstruction in asthma [ J]. Curr Opin Allergy Clin Immunol, 2008,8 (1) :63-69.
10Boxall C, Holgate S T, Davies D E. The contribution of transforming growth factor-beta and epidermal growth factor signalling to air~ay remodelling in chronic asthma[ J]. Eur Respir J,2006,27 ( 1 ) :208-229.
